Baxter received marketing authorization from the European Commission for a new 10% ready-to-use ivig solution in January 2006.

Please consult your healthcare professional for more information.

Subcutaneous Therapy

Home self therapy with subcutaneous immunoglobulin increases flexibility and independence for patients.

>> Learn more about Subcutaneous Therapy

European Primary Immunodeficiencies Consensus Statement

On 19-20 June 2006, more than 100 medical professionals, health policy experts, and experts gathered to develop public health strategies for Primary Immunodeficiencies (PID). The Consensus Statement containing the conclusions and recommendations are now available in 10 languages on the EU PID website.

The information given on the website is for international use. This may not apply to all countries. For specific information related to your country please contact the Baxter representative in your country.